# Drug development is modular, but sponsors keep ultimate responsibility

> Original title: Drug development is increasingly modular, but ultimate responsibility remains with the sponsor. In our latest article, we explore why own...

- Source: X search: AI startup funding (we raised, seed, Series A)
- Published: 2026-11-05T07:03:15.000Z
- Bad Influence: https://badinfluence.news/items/ma3rqccs3hi9mfyk6ilticg5l
- Original: https://x.com/LifeNetwork_AI/status/2118237691921748078

## Summary

The article argues that drug development is increasingly organized as a network of specialist partners, while sponsors retain ultimate responsibility under ICH GCP E6(R3). It cites Mithril Medicine's one-employee model coordinating 11 external labs with Claude, and Formation Bio's $600 million fund aiming for 10 to 15 clinical-stage programs. It also cites FDA and EMA actions against CROs Synchron, Panexcell and Synapse Labs, showing how one provider's failure can reach many sponsors.

## Post

Drug development is increasingly modular, but ultimate responsibility remains with the sponsor. In our latest article, we explore why ownership is only half the problem, and what independent institutions can build together through federated infrastructure. https://x.com/i/article/2118236681681907712